Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Non-small cell lung cancer
EGFR, ALK, KRAS G12C and the ADC wave in first and later lines.
Live from ClinicalTrials.gov, fetched 2026-11-11 14:56 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
600
the 600 most recently updated are shown
For relapsed or refractory disease
4%
21 trial titles name relapsed, refractory or recurrent disease
Led by industry
65%
390 trials with a company as lead sponsor
145 of the 600 non-small cell lung cancer trials are Phase 3; 31 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of non-small cell lung cancer (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 105 of 600 trials name no segment and are listed as Untagged.
Segment:All1L1L · Advanced or metastatic1L · Locally advanced1L · Maintenance2L+2L+ · Advanced or metastatic2L+ · Locally advanced2L+ · Relapsed or refractoryAdjuvantAdvanced or metastaticALKALK · AdjuvantALK · Advanced or metastaticALK · Relapsed or refractoryEGFREGFR · 1L · Advanced or metastaticEGFR · 1L · Locally advancedEGFR · 2L+EGFR · 2L+ · Advanced or metastaticEGFR · 2L+ · Locally advancedEGFR · AdjuvantEGFR · Advanced or metastaticEGFR · Locally advancedEGFR · Neoadjuvant or perioperative
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Pembrolizumab NovoCure GmbH | Advanced or metastatic | Antibody | Ph3 | NCT06216301, NCT05479812, NCT06561685, NCT05816252 +23 |
| Pembrolizumab Merck Sharp & Dohme LLC | Untagged | Antibody | Ph3 | NCT06312137, NCT05492682, NCT04267848, NCT06623422 +14 |
| Pembrolizumab Daiichi Sankyo | 1L · Advanced or metastatic | Antibody | Ph3 | NCT05555732, NCT05565378, NCT05920356, NCT07777822 +7 |
| Durvalumab Merck Sharp & Dohme LLC | Untagged | Antibody | Ph3 | NCT07554339, NCT06083454, NCT06498635, NCT06667908 +5 |
| Nivolumab M.D. Anderson Cancer Center | Advanced or metastatic | Antibody | Ph3 | NCT02696993, NCT07902921, NCT04180371, NCT07770100 +5 |
| Pembrolizumab Daiichi Sankyo | Locally advanced | Antibody | Ph3 | NCT07739966, NCT04198766, NCT04198766, NCT06545331 +4 |
| Atezolizumab Genentech, Inc. | Untagged | Antibody | Ph3 | NCT04302025, NCT07388524, NCT07388524, NCT04214262 +3 |
| Durvalumab Bristol-Myers Squibb | Locally advanced | Antibody | Ph3 | NCT07361497, NCT05221840, NCT05170204, NCT03999710 +3 |
| Cemiplimab Medical University of South Carolina | Untagged | Antibody | Ph3 | NCT07720167, NCT06465329, NCT06918132, NCT05317858 +2 |
| Nab-paclitaxel National Cancer Institute (NCI) | Advanced or metastatic | Other or not recognised | Ph3 | NCT06096844, NCT06996782, NCT06731907, NCT06447662 +2 |
| Osimertinib Daiichi Sankyo | EGFR · Locally advanced | Small molecule | Ph3 | NCT04676477, NCT04676477, NCT04676477, NCT06417814 +2 |
| Pembrolizumab Merck Sharp & Dohme LLC | PD-L1 · 1L · Advanced or metastatic | Antibody | Ph3 | NCT04165083, NCT06357533, NCT07361510, NCT07877584 +2 |
| Ipilimumab M.D. Anderson Cancer Center | Advanced or metastatic | Antibody | Ph3 | NCT02696993, NCT07770100, NCT05176483, NCT05715229 +1 |
| Adagrasib Mirati Therapeutics Inc. | KRAS G12C · Advanced or metastatic | Small molecule | Ph2/Ph3 | NCT04613596, NCT04613596, NCT04613596, NCT04613596 |
| Amivantamab Janssen Research & Development, LLC | EGFR · Advanced or metastatic | Bispecific antibody | Ph3 | NCT02609776, NCT02609776, NCT04538664, NCT05498428 |
| Osimertinib Wayshine Biopharm, Inc. | Untagged | Small molecule | Ph3 | NCT07206498, NCT07680790, NCT07874490, NCT03381274 |
| Pembrolizumab Boehringer Ingelheim | HER2 · Advanced or metastatic | Antibody | Ph3 | NCT07486817, NCT06452277, NCT04561362, NCT06151574 |
| Pembrolizumab AstraZeneca | 1L · Locally advanced | Antibody | Ph3 | NCT06692738, NCT06627647, NCT07756645, NCT07865910 |
| daraxonrasib Revolution Medicines, Inc. | Advanced or metastatic | Small molecule | Ph3 | NCT06881784, NCT07397338, NCT07397338 |
| Datopotamab Deruxtecan Daiichi Sankyo | 1L · Advanced or metastatic | Antibody-drug conjugate | Ph3 | NCT05555732, NCT05687266, NCT05215340 |
| Lazertinib Janssen Research & Development, LLC | EGFR · Advanced or metastatic | Small molecule | Ph3 | NCT02609776, NCT05388669, NCT05498428 |
| Nab-paclitaxel Peking University People's Hospital | Neoadjuvant or perioperative | Other or not recognised | Ph3 | NCT07885709, NCT03456063, NCT07863999 |
| Nivolumab InSightec | Untagged | Antibody | Ph3 | NCT05317858, NCT02595944, NCT06047379 |
| Osimertinib National Cancer Institute (NCI) | EGFR · Relapsed or refractory | Small molecule | Ph3 | NCT04181060, NCT03191149, NCT03410043 |
| Pembrolizumab Hoffmann-La Roche | KRAS G12C · 1L · Advanced or metastatic | Antibody | Ph3 | NCT06793215, NCT05789082, NCT06119581 |
| Pembrolizumab Merck Sharp & Dohme LLC | PD-L1 · Advanced or metastatic | Antibody | Ph3 | NCT06170788, NCT07360743, NCT04738487 |
| Pembrolizumab National Cancer Institute (NCI) | 1L · Maintenance | Antibody | Ph3 | NCT03793179, NCT07845786, NCT03976323 |
| Sacituzumab tirumotecan Merck Sharp & Dohme LLC | Untagged | Antibody | Ph3 | NCT06312137, NCT06788912, NCT07286149 |
| Tislelizumab ImmunityBio, Inc. | Advanced or metastatic | Antibody | Ph3 | NCT06745908, NCT05635708, NCT07715396 |
| Zongertinib Boehringer Ingelheim | HER2 · Advanced or metastatic | Small molecule | Ph3 | NCT07486817, NCT04886804, NCT06151574 |
| adebrelimab Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Neoadjuvant or perioperative | Antibody | Ph3 | NCT07863167, NCT07895238 |
| Amivantamab Janssen Research & Development, LLC | EGFR · Locally advanced | Bispecific antibody | Ph3 | NCT04988295, NCT06667076 |
| Bevacizumab Genmab | EGFR · Relapsed or refractory | Antibody | Ph3 | NCT05579366, NCT04181060 |
| Calderasib Merck Sharp & Dohme LLC | Untagged | Small molecule | Ph3 | NCT07190248, NCT07554339 |
| Divarasib Hoffmann-La Roche | KRAS G12C · 1L · Advanced or metastatic | Small molecule | Ph3 | NCT06793215, NCT05789082 |
| Durvalumab AstraZeneca | EGFR | Antibody | Ph3 | NCT03833154, NCT04538378 |
| Durvalumab National Cancer Institute (NCI) | Relapsed or refractory | Antibody | Ph3 | NCT04092283, NCT03581487 |
| Durvalumab City of Hope Medical Center | 1L · Advanced or metastatic | Antibody | Ph3 | NCT07288034, NCT05687266 |
| furmonertinib ArriVent BioPharma, Inc. | EGFR · Locally advanced | Small molecule | Ph3 | NCT05607550, NCT05607550 |
| Intismeran autogene Merck Sharp & Dohme LLC | Untagged | Other or not recognised | Ph3 | NCT06623422, NCT06077760 |
| Lazertinib Janssen Research & Development, LLC | EGFR · Locally advanced | Small molecule | Ph3 | NCT04988295, NCT06667076 |
| osimertinib Jiangsu Aosaikang Pharmaceutical Co., Ltd. | EGFR · 1L · Locally advanced | Small molecule | Ph3 | NCT07897188, NCT07005102 |
| Pembrolizumab Hoffmann-La Roche | KRAS G12C · Adjuvant | Antibody | Ph3 | NCT07541170, NCT06890598 |
| Pembrolizumab Genmab | PD-L1 · Locally advanced | Antibody | Ph3 | NCT06635824, NCT03881488 |
| Pembrolizumab Kanvas Biosciences | PD-L1 | Antibody | Ph3 | NCT07910942, NCT06758401 |
| Pembrolizumab Mirati Therapeutics Inc. | KRAS G12C · Advanced or metastatic | Antibody | Ph2/Ph3 | NCT04613596, NCT06162221 |
| Pembrolizumab AstraZeneca | HER2 · Locally advanced | Antibody | Ph3 | NCT05048797, NCT04585750 |
| PF-08634404 Pfizer | Locally advanced | Other or not recognised | Ph3 | NCT07222566, NCT07489066 |
| Pumitamig BioNTech SE | Untagged | Other or not recognised | Ph2/Ph3 | NCT06712316, NCT07871214 |
| Ramucirumab National Cancer Institute (NCI) | Relapsed or refractory | Antibody | Ph2/Ph3 | NCT04310007, NCT06616584 |
| Rescue Medications Merck Sharp & Dohme LLC | Untagged | Other or not recognised | Ph3 | NCT07908537, NCT07286149 |
| Rilvegostomig AstraZeneca | 1L · Locally advanced | Other or not recognised | Ph3 | NCT06692738, NCT06627647 |
| Rilvegostomig AstraZeneca | PD-L1 · 1L · Advanced or metastatic | Other or not recognised | Ph3 | NCT06357533, NCT06868277 |
| TAS6417 Taiho Oncology, Inc. | EGFR · Advanced or metastatic | Other or not recognised | Ph3 | NCT05973773, NCT05967689 |
| Telisotuzumab Vedotin AbbVie | MET · 2L+ | Antibody-drug conjugate | Ph3 | NCT04928846, NCT06568939 |
| 7MW3711 Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced or metastatic | Other or not recognised | Ph3 | NCT07831863 |
| ABBV-1480 AbbVie | 1L · Locally advanced | Other or not recognised | Ph3 | NCT07756645 |
| Acasunlimab Genmab | PD-L1 · Locally advanced | Antibody | Ph3 | NCT06635824 |
| Acetaminophen Merck Sharp & Dohme LLC | EGFR · 2L+ · Advanced or metastatic | Other or not recognised | Ph3 | NCT06305754 |
| Adagrasib Mirati Therapeutics Inc. | KRAS G12C · 1L | Small molecule | Ph3 | NCT06875310 |
Showing the 60 most advanced of 1014 programs.
Assets over time
600 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Pembrolizumab | NovoCure GmbH | |
| Durvalumab | William Zeitler | |
| Atezolizumab | National Cancer Institute (NCI) | |
| Cemiplimab | Medical University of South Carolina | |
| Nivolumab | Bristol-Myers Squibb | |
| Amivantamab | Janssen Research & Development, LLC | |
| Datopotamab Deruxtecan | Daiichi Sankyo | |
| JDQ443 | Novartis Pharmaceuticals | |
| Pumitamig | Bristol-Myers Squibb | |
| Rilvegostomig | AstraZeneca | |
| Calderasib | Merck Sharp & Dohme LLC | |
| Ipilimumab | M.D. Anderson Cancer Center | |
| Zongertinib | Boehringer Ingelheim | |
| Lazertinib | Janssen Research & Development, LLC | |
| Tislelizumab | BeiGene | |
| BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Telisotuzumab Adizutecan | AbbVie | |
| Alectinib | Genentech, Inc. | |
| Sacituzumab tirumotecan | Merck Sharp & Dohme LLC | |
| Divarasib | Hoffmann-La Roche | |
| Ramucirumab | Abramson Cancer Center at Penn Medicine | |
| TAS6417 | Taiho Oncology, Inc. | |
| Firmonertinib | ArriVent BioPharma, Inc. | |
| Adagrasib | Mirati Therapeutics Inc. | |
| Trastuzumab Deruxtecan | Daiichi Sankyo | |
| PF-08634404 | Pfizer | |
| Iza-bren | Bristol-Myers Squibb | |
| daraxonrasib | Revolution Medicines, Inc. | |
| Nab-paclitaxel | National Cancer Institute (NCI) | |
| Acasunlimab | Genmab |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT07908537 A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) No sites listed Decision brief → | Ph3 | Merck Sharp & Dohme LLC | not yet recruiting | 2026-11-02 | 2031-12-08 |
| NCT07908745 Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC No sites listed Decision brief → | Ph3 | Ruijin Hospital | not yet recruiting | 2026-11-02 | 2030-12-30 |
| ES-SPARE · NCT07908732 Risk-Adapted Segmental Esophagus-Sparing Radiotherapy for Definitive Non-Small Cell Lung Cancer No sites listed Decision brief → | Ph3 | Ruijin Hospital | not yet recruiting | 2026-11-02 | 2031-06-30 |
| NCT07897188 ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Single-country: China (1 site) Decision brief → | Ph3 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | not yet recruiting | 2026-10-27 | 2030-12-30 |
| NCT07895992 SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study Single-country: China (1 site) Decision brief → | Ph3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | not yet recruiting | 2026-10-26 | 2028-12-30 |
| NCT07896005 A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer Single-country: China (2 sites) Decision brief → | Ph3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | not yet recruiting | 2026-10-26 | 2031-02 |
| NCT07895238 A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC No sites listed Decision brief → | Ph3 | West China Hospital | not yet recruiting | 2026-10-26 | 2032-12-31 |
| REACH · NCT07888075 Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC No sites listed Decision brief → | Ph2/Ph3 | AVEO Pharmaceuticals, Inc. | not yet recruiting | 2026-10-22 | 2030-03 |
| IFEM · NCT07877584 PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% No sites listed Decision brief → | Ph3 | German Cancer Research Center | not yet recruiting | 2026-10-16 | 2033-11-30 |
| NCT07865910 A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Single-country: China (16 sites) Decision brief → | Ph2/Ph3 | Shanghai Henlius Biotech | not yet recruiting | 2026-10-08 | 2030-12-30 |
| NCT07863999 Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC Single-country: China (5 sites) Decision brief → | Ph3 | Shanghai Pulmonary Hospital, Shanghai, China | recruiting | 2026-10-07 | 2033-12-01 |
| NCT07833202 A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation Single-country: China (1 site) Decision brief → | Ph3 | Shanghai Jeyou Pharmaceutical Co., Ltd. | not yet recruiting | 2026-09-22 | 2029-04 |
| NCT07829549 Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations Single-country: China (1 site) Decision brief → | Ph3 | RemeGen Co., Ltd. | not yet recruiting | 2026-09-21 | 2031-04 |
| NCT07831863 A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy Single-country: China (1 site) Decision brief → | Ph3 | Mabwell (Shanghai) Bioscience Co., Ltd. | not yet recruiting | 2026-09-21 | 2029-03 |
| NCT07821684 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer No sites listed Decision brief → | Ph3 | AbbVie | not yet recruiting | 2026-09-16 | 2030-03 |
| NCT07822542 A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer No sites listed Decision brief → | Ph3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | not yet recruiting | 2026-09-16 | 2030-05-31 |
| NCT07816380 A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer No sites listed Decision brief → | Ph3 | Guangzhou JOYO Pharma Co., Ltd | not yet recruiting | 2026-09-11 | 2028-12-30 |
| RASolve 308 · NCT07777822 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC Single-country: United States (4 sites) Decision brief → | Ph3 | Revolution Medicines, Inc. | recruiting | 2026-08-20 | 2029-10 |
| NCT07754123 Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC Single-country: China (1 site) Decision brief → | Ph3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | recruiting | 2026-08-10 | 2028-08-31 |
| NCT07756645 A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants 2 countries, 50% of sites in the US Decision brief → | Ph3 | AbbVie | recruiting | 2026-08-10 | 2029-12 |
| NCT07739186 A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) Single-country: China (2 sites) Decision brief → | Ph2/Ph3 | Sichuan Baili Pharmaceutical Co., Ltd. | not yet recruiting | 2026-07-31 | 2029-12 |
| NCT07718737 Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy 2 countries, 29% of sites in the US Decision brief → | Ph2/Ph3 | Multitude Therapeutics Inc. | recruiting | 2026-07-22 | 2028-03-30 |
| High Five · NCT07715396 Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden Single-country: Germany (1 site) Decision brief → | Ph3 | AIO-Studien-gGmbH | not yet recruiting | 2026-07-20 | 2031-10-30 |
| NCT07680790 Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) 16 countries, 19% of sites in the US Decision brief → | Ph3 | Bristol-Myers Squibb | recruiting | 2026-07-02 | 2031-12-30 |
| NCT07566052 A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation 3 countries, 27% of sites in the US Decision brief → | Ph3 | Astellas Pharma Global Development, Inc. | recruiting | 2026-05-04 | 2030-06-30 |
| NCT07554339 A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) 18 countries, 6% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2026-04-28 | 2032-12-15 |
| KRASCENDO 3 · NCT07541170 A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) 19 countries, 10% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | recruiting | 2026-04-21 | 2032-01-31 |
| INTerpath-014 · NCT07513376 A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) 20 countries, 21% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2026-04-07 | 2034-08-22 |
| KANDLELIT-013 · NCT07431827 MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) 19 countries, 0% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2026-02-25 | 2039-10-26 |
| NCT07388524 Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Single-country: United States (145 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | recruiting | 2026-02-05 | 2032-09-30 |
| TeLuRide-008 · NCT07365319 A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. 11 countries, 43% of sites in the US Decision brief → | Ph2/Ph3 | Eikon Therapeutics | recruiting | 2026-01-26 | 2035-12-31 |
| NCT07361497 A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) 32 countries, 15% of sites in the US Decision brief → | Ph3 | Bristol-Myers Squibb | recruiting | 2026-01-23 | 2030-09-18 |
| NCT07361510 A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) 36 countries, 14% of sites in the US Decision brief → | Ph3 | Bristol-Myers Squibb | recruiting | 2026-01-23 | 2031-10-14 |
| NCT07361484 Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) No sites listed Decision brief → | Ph3 | BeyondSpring Pharmaceuticals Inc. | not yet recruiting | 2026-01-23 | 2029-06-01 |
| TROPION-Lung17 · NCT07291037 Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations 21 countries, 25% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2025-12-18 | 2029-01-29 |
| NCT07222566 Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer 20 countries, 47% of sites in the US Decision brief → | Ph3 | Pfizer | recruiting | 2025-10-30 | 2029-02-27 |
| MarsLight-11 · NCT07217301 A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer 3 countries, 24% of sites in the US Decision brief → | Ph3 | Takeda | recruiting | 2025-10-15 | 2028-11-01 |
| NCT07195695 Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations 28 countries, 14% of sites in the US Decision brief → | Ph3 | Boehringer Ingelheim | recruiting | 2025-09-29 | 2032-02-26 |
| NCT07190248 A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) 30 countries, 8% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2025-09-24 | 2029-12-07 |
| NCT07185997 Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations 17 countries, 15% of sites in the US Decision brief → | Ph3 | ArriVent BioPharma, Inc. | recruiting | 2025-09-22 | 2029-02 |
| NCT07183189 A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC Single-country: China (1 site) Decision brief → | Ph3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | active not recruiting | 2025-09-19 | 2032-11 |
| NCT07162883 Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) 13 countries, 0% of sites in the US Decision brief → | Ph3 | Qilu Pharmaceutical Co., Ltd. | active not recruiting | 2025-09-09 | 2026-12-31 |
| NCT07155187 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer 20 countries, 14% of sites in the US Decision brief → | Ph2/Ph3 | AbbVie | recruiting | 2025-09-04 | 2030-09 |
| NCT07149649 Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) Single-country: Switzerland (9 sites) Decision brief → | Ph2/Ph3 | Swiss Cancer Institute | recruiting | 2025-09-02 | 2031-01-01 |
| NCT07144280 A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) 29 countries, 56% of sites in the US Decision brief → | Ph3 | Pfizer | recruiting | 2025-08-27 | 2028-03-10 |
| PRIME-Lung · NCT07135882 Primary Radiotherapy In MEtastatic Lung Cancer Single-country: Australia (6 sites) Decision brief → | Ph3 | Trans Tasman Radiation Oncology Group | recruiting | 2025-08-22 | 2030-12-31 |
| REZILIENT4 · NCT07128199 A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection 24 countries, 12% of sites in the US Decision brief → | Ph3 | Taiho Oncology, Inc. | recruiting | 2025-08-17 | 2029-10-01 |
| NCT07100080 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) 25 countries, 15% of sites in the US Decision brief → | Ph2/Ph3 | Bristol-Myers Squibb | recruiting | 2025-08-03 | 2028-12-15 |
| MountainTAP-29 · NCT07063745 A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion 34 countries, 14% of sites in the US Decision brief → | Ph2/Ph3 | Bristol-Myers Squibb | recruiting | 2025-07-14 | 2031-08-12 |
| NCT07005102 A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer 13 countries, 28% of sites in the US Decision brief → | Ph2/Ph3 | AbbVie | recruiting | 2025-06-05 | 2036-11 |
| ALBORAN · NCT06992609 Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. Single-country: Spain (14 sites) Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2025-05-28 | 2029-06-30 |
| ARCH · NCT06931717 A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy 9 countries, 0% of sites in the US Decision brief → | Ph3 | ETOP IBCSG Partners Foundation | recruiting | 2025-04-17 | 2029-03 |
| DESTINY-Lung06 · NCT06899126 Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer 24 countries, 11% of sites in the US Decision brief → | Ph3 | Daiichi Sankyo | recruiting | 2025-03-27 | 2030-04-24 |
| SUNRAY-02 · NCT06890598 Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer 29 countries, 25% of sites in the US Decision brief → | Ph3 | Eli Lilly and Company | recruiting | 2025-03-24 | 2029-05 |
| RASolve 301 · NCT06881784 Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) 19 countries, 27% of sites in the US Decision brief → | Ph3 | Revolution Medicines, Inc. | recruiting | 2025-03-18 | 2027-12-01 |
| NCT06875310 A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) 35 countries, 15% of sites in the US Decision brief → | Ph3 | Mirati Therapeutics Inc. | recruiting | 2025-03-13 | 2029-09-07 |
| ARTEMIDELung04 · NCT06868277 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer 27 countries, 13% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2025-03-10 | 2030-01-17 |
| OliGRAIL · NCT06840782 First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. Single-country: France (11 sites) Decision brief → | Ph3 | Gustave Roussy, Cancer Campus, Grand Paris | recruiting | 2025-02-21 | 2030-02 |
| Krascendo 2 · NCT06793215 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer 28 countries, 23% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | recruiting | 2025-01-27 | 2028-11-30 |
| HARMONi-7 · NCT06767514 Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 17 countries, 34% of sites in the US Decision brief → | Ph3 | Summit Therapeutics | recruiting | 2025-01-10 | 2028-04 |
| ALKAZAR · NCT06765109 Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC 29 countries, 14% of sites in the US Decision brief → | Ph3 | Nuvalent Inc. | recruiting | 2025-01-09 | 2029-12 |
| NCT06758401 This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. 31 countries, 22% of sites in the US Decision brief → | Ph3 | Pfizer | recruiting | 2025-01-03 | 2028-09-05 |
| NCT06745908 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy 3 countries, 65% of sites in the US Decision brief → | Ph3 | ImmunityBio, Inc. | recruiting | 2024-12-20 | 2028-09 |
| NCT06732401 Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer Single-country: United States (192 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2024-12-13 | 2028-06-30 |
| NCT06712316 Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02) 22 countries, 15% of sites in the US Decision brief → | Ph2/Ph3 | BioNTech SE | recruiting | 2024-12-02 | 2029-01 |
| NCT06692738 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 26 countries, 23% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2024-11-18 | 2030-07-01 |
| NCT06635824 Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) 27 countries, 15% of sites in the US Decision brief → | Ph3 | Genmab | active not recruiting | 2024-10-10 | 2027-07-30 |
| NCT06627647 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC 25 countries, 26% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2024-10-04 | 2030-11-18 |
| NCT06623422 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) 31 countries, 22% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2024-10-02 | 2033-05-16 |
| NCT06616584 Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) Single-country: United States (413 sites) Decision brief → | Ph2/Ph3 | SWOG Cancer Research Network | recruiting | 2024-09-27 | 2027-12-31 |
| TROPION-Lung12 · NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features 10 countries, 41% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2024-08-21 | 2026-07-10 |
| RELATIVITY1093 · NCT06561386 A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% 31 countries, 18% of sites in the US Decision brief → | Ph3 | Bristol-Myers Squibb | recruiting | 2024-08-20 | 2030-07-30 |
| NCT06498635 Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial Single-country: United States (284 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | recruiting | 2024-07-12 | 2039-07-15 |
| ARTEMIA · NCT06472245 Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor 14 countries, 38% of sites in the US Decision brief → | Ph3 | OSE Immunotherapeutics | recruiting | 2024-06-25 | 2027-12-15 |
| SOHO-02 · NCT06452277 A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) 36 countries, 9% of sites in the US Decision brief → | Ph3 | Bayer | recruiting | 2024-06-11 | 2027-10-28 |
| NCT06422143 Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] 26 countries, 10% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2024-05-20 | 2029-01-12 |
| TROPION-Lung15 · NCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer 24 countries, 4% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2024-05-16 | 2027-01-11 |
| TROPION-Lung10 · NCT06357533 Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations 21 countries, 22% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2024-04-10 | 2029-12-28 |
| NCT06348199 A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer 14 countries, 0% of sites in the US Decision brief → | Ph3 | Samsung Bioepis Co., Ltd. | active not recruiting | 2024-04-04 | 2026-03-10 |
| NCT06345729 A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) 30 countries, 6% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2024-04-03 | 2028-01-24 |
| TroFuse-019 · NCT06312137 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) 31 countries, 19% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2024-03-15 | 2034-02-21 |
| NCT06305754 Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) 19 countries, 11% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | active not recruiting | 2024-03-12 | 2028-08-17 |
| ADOPT-lung · NCT06284317 A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. 10 countries, 0% of sites in the US Decision brief → | Ph3 | ETOP IBCSG Partners Foundation | recruiting | 2024-02-28 | 2029-10 |
| LIVIGNO-4 · NCT06236438 Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 12 countries, 31% of sites in the US Decision brief → | Ph2/Ph3 | AbbVie | active not recruiting | 2024-02-01 | 2031-10 |
| LUNAR-2 · NCT06216301 LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC 17 countries, 36% of sites in the US Decision brief → | Ph3 | NovoCure GmbH | recruiting | 2024-01-22 | 2028-10 |
| TroFuse-007 · NCT06170788 Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) 26 countries, 7% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | recruiting | 2023-12-14 | 2028-01-25 |
| NCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment 26 countries, 13% of sites in the US Decision brief → | Ph3 | Boehringer Ingelheim | active not recruiting | 2023-11-30 | 2026-12-10 |
| NCT06140836 A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) 21 countries, 5% of sites in the US Decision brief → | Ph3 | Bristol-Myers Squibb | active not recruiting | 2023-11-20 | 2027-02-16 |
| SUNRAY-01 · NCT06119581 A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer 29 countries, 21% of sites in the US Decision brief → | Ph3 | Eli Lilly and Company | recruiting | 2023-11-07 | 2027-11 |
| NCT06096844 Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial Single-country: United States (330 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | recruiting | 2023-10-24 | 2039-04-01 |
| INTerpath-002 · NCT06077760 A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) 33 countries, 30% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | active not recruiting | 2023-10-11 | 2030-06-25 |
| Drugs-SNPs · NCT05987956 Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms Single-country: United States (2 sites) Decision brief → | Ph2/Ph3 | Medicine Invention Design, Inc | active not recruiting | 2023-08-14 | 2026-11-18 |
| eVOLVE-Lung02 · NCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. 25 countries, 11% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2023-08-09 | 2026-08-17 |
| REZILIENT3 · NCT05973773 REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) 22 countries, 7% of sites in the US Decision brief → | Ph3 | Taiho Oncology, Inc. | active not recruiting | 2023-08-03 | 2027-05-27 |
| NCT05920356 A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) 38 countries, 6% of sites in the US Decision brief → | Ph3 | Amgen | recruiting | 2023-06-27 | 2027-06-30 |
| NCT05899608 Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients 17 countries, 29% of sites in the US Decision brief → | Ph3 | Summit Therapeutics | active not recruiting | 2023-06-12 | 2028-12-31 |
| AVANZAR · NCT05687266 Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations 23 countries, 20% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2023-01-18 | 2027-11-01 |
| NCT05668988 A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) 15 countries, 10% of sites in the US Decision brief → | Ph3 | Dizal Pharmaceuticals | active not recruiting | 2022-12-30 | 2026-01-16 |
| NCT05607550 Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) 19 countries, 33% of sites in the US Decision brief → | Ph3 | ArriVent BioPharma, Inc. | active not recruiting | 2022-11-07 | 2026-10-06 |
| NCT05555732 Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) 29 countries, 14% of sites in the US Decision brief → | Ph3 | Daiichi Sankyo | active not recruiting | 2022-09-27 | 2029-05-11 |
| neoSCORE Ⅱ · NCT05429463 Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） Single-country: China (1 site) Decision brief → | Ph3 | Second Affiliated Hospital, Zhejiang University, School of Medicine | active not recruiting | 2022-06-23 | 2026-11-30 |
| PALOMA-3 · NCT05388669 A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer 20 countries, 9% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2022-05-24 | 2024-01-03 |
| PINNACLE · NCT05378763 A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations Single-country: United States (1 site) Decision brief → | Ph3 | Spectrum Pharmaceuticals, Inc | suspended | 2022-05-18 | 2027-12-25 |
| LIMITLESS · NCT05317858 Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets 3 countries, 75% of sites in the US Decision brief → | Ph3 | InSightec | recruiting | 2022-04-08 | 2031-06-01 |
| PACIFIC-9 · NCT05221840 A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer 20 countries, 16% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2022-02-03 | 2027-01-08 |
| TROPION-Lung08 · NCT05215340 Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations 28 countries, 13% of sites in the US Decision brief → | Ph3 | Daiichi Sankyo | active not recruiting | 2022-01-31 | 2030-03-04 |
| HORIZON 1 · NCT05170204 A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) 19 countries, 4% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | active not recruiting | 2021-12-27 | 2027-01-19 |
| KontRASt-02 · NCT05132075 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer 25 countries, 2% of sites in the US Decision brief → | Ph3 | Novartis Pharmaceuticals | terminated | 2021-11-24 | 2026-09-03 |
| NCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations 20 countries, 15% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2021-09-17 | 2026-06-09 |
| NCT05047250 A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer Single-country: China (18 sites) Decision brief → | Ph3 | Hoffmann-La Roche | active not recruiting | 2021-09-17 | 2025-12-30 |
| SANOVO · NCT05009836 Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Single-country: China (1 site) Decision brief → | Ph3 | Hutchmed | active not recruiting | 2021-08-18 | 2028-05-30 |
| MARIPOSA-2 · NCT04988295 A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure 29 countries, 11% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2021-08-03 | 2023-07-10 |
| NCT04956692 Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) 16 countries, 14% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | completed | 2021-07-09 | 2023-04-04 |
| NCT04929041 Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative Single-country: United States (169 sites) Decision brief → | Ph2/Ph3 | National Cancer Institute (NCI) | active not recruiting | 2021-06-18 | 2030-12-12 |
| NCT04928846 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 32 countries, 16% of sites in the US Decision brief → | Ph3 | AbbVie | recruiting | 2021-06-16 | 2028-12 |
| NCT04738487 Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) 23 countries, 4% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | terminated | 2021-02-04 | 2024-09-05 |
| NCT04613596 Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 47 countries, 29% of sites in the US Decision brief → | Ph2/Ph3 | Mirati Therapeutics Inc. | recruiting | 2020-11-03 | 2028-10-31 |
| NCT04585490 Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC Single-country: United States (1 site) Decision brief → | Ph3 | Stanford University | recruiting | 2020-10-14 | 2026-12 |
| PAPILLON · NCT04538664 A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions 26 countries, 7% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2020-09-04 | 2023-05-03 |
| MARIPOSA · NCT04487080 A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer 28 countries, 7% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2020-07-27 | 2023-08-11 |
| SKYSCRAPER-01 · NCT04294810 A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer 23 countries, 6% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | completed | 2020-03-04 | 2025-12-30 |
| NCT04267848 Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) 2 countries, 100% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | recruiting | 2020-02-13 | 2030-01-31 |
| NCT04214262 Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Single-country: United States (390 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2020-01-02 | 2024-08-24 |
| LIBRETTO-431 · NCT04194944 A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer 26 countries, 0% of sites in the US Decision brief → | Ph3 | Eli Lilly and Company | active not recruiting | 2019-12-11 | 2023-05-01 |
| NCT04181060 Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer Single-country: United States (604 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | recruiting | 2019-11-29 | 2029-06-30 |
| NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations 24 countries, 8% of sites in the US Decision brief → | Ph3 | Takeda | completed | 2019-10-16 | 2026-09-22 |
| NCT04092283 Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer 2 countries, 100% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2019-09-17 | 2028-12-31 |
| NCT03976323 Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) 20 countries, 11% of sites in the US Decision brief → | Ph3 | Merck Sharp & Dohme LLC | completed | 2019-06-06 | 2024-02-07 |
| NCT03937154 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer 10 countries, 6% of sites in the US Decision brief → | Ph3 | Amgen | active not recruiting | 2019-05-03 | 2026-03-10 |
| SAPPHIRE · NCT03906071 Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer 12 countries, 51% of sites in the US Decision brief → | Ph3 | Mirati Therapeutics Inc. | terminated | 2019-04-08 | 2023-03-20 |
| PACIFIC-4 · NCT03833154 Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation 20 countries, 38% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2019-02-06 | 2028-10-31 |
| NCT03815643 Avelumab Program Rollover Study 22 countries, 25% of sites in the US Decision brief → | Ph3 | EMD Serono Research & Development Institute, Inc. | active not recruiting | 2019-01-24 | 2026-11-24 |
| NCT03793179 Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer 3 countries, 99% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2019-01-04 | 2027-09-30 |
| NCT03743064 A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2 8 countries, 29% of sites in the US Decision brief → | Ph3 | Helsinn Healthcare SA | completed | 2018-11-15 | 2022-12-27 |
| NCT03743051 A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1 7 countries, 33% of sites in the US Decision brief → | Ph3 | Helsinn Healthcare SA | completed | 2018-11-15 | 2023-02-11 |
| NCT03637816 Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer Single-country: United States (1 site) Decision brief → | Ph2/Ph3 | M.D. Anderson Cancer Center | active not recruiting | 2018-08-20 | 2026-12-31 |
| NCT03456076 A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer 27 countries, 3% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | active not recruiting | 2018-03-07 | 2023-06-26 |
| NCT03456063 A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) 24 countries, 21% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | completed | 2018-03-07 | 2025-10-01 |
| NCT03391869 Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Single-country: United States (5 sites) Decision brief → | Ph3 | M.D. Anderson Cancer Center | active not recruiting | 2018-01-05 | 2027-03-31 |
| NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer 9 countries, 7% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | completed | 2017-06-21 | 2025-09-18 |
| ANVIL · NCT02595944 Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) Single-country: United States (884 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2015-11-04 | 2027-05-31 |
| NCT02486718 Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] 22 countries, 21% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | completed | 2015-07-01 | 2024-01-26 |
| RELAY · NCT02411448 A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) 14 countries, 7% of sites in the US Decision brief → | Ph3 | Eli Lilly and Company | active not recruiting | 2015-04-08 | 2019-01-23 |
| SELECT-1 · NCT01933932 Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC 26 countries, 9% of sites in the US Decision brief → | Ph3 | AstraZeneca | active not recruiting | 2013-09-02 | 2016-06-07 |
| CAN3001 · NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) 29 countries, 19% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2013-03-05 | 2026-12-31 |
| NCT07919691 Proton Moderately Hypofractionated Radiotherapy in NSCLC Patients Unable to Tolerate Standard Concurrent Chemoradiotherapy No sites listed Decision brief → | Ph2 | Ruijin Hospital | not yet recruiting | 2026-11-05 | 2030-06-30 |
| NCT07917767 A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small Cell Lung Cancer No sites listed Decision brief → | Ph2 | Tang-Du Hospital | not yet recruiting | 2026-11-05 | 2028-12-31 |
| NCT07912593 Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Ensem Therapeutics | recruiting | 2026-11-03 | 2028-10-30 |
| NCT07911449 Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases Single-country: Vietnam (1 site) Decision brief → | Ph2 | Cho Ray Hospital | recruiting | 2026-11-02 | 2028-10-30 |
| APOLLO · NCT07909031 CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | Crescent Biopharma, Inc. | recruiting | 2026-11-02 | 2028-10 |